Abstract:Background:Only about half of patients with type 2 diabetes treated with antihyperglycemic drugs achieve glycemic control (HbA1c <7%), most commonly due to poor treatment adherence. Glucagon-like peptide-1 (GLP-1) receptor agonists act on multiple targets involved in glucose homeostasis and have a low risk of causing hypoglycemia. While GLP-1 receptor (GLP-1R) agonists share the same mechanism of action, clinical profiles of individual agents differ, particularly between short- and long-acting agents. In this article, recent findings regarding the pharmacology of GLP-1 agonists are reviewed, and the clinical effects of short- versus long-acting agents are compared.Data sources:Relevant articles were identified through a search of PubMed using the keywords glucagon-like peptide-1, GLP-1, glucagon-like peptide-1 receptor agonist, GLP-1R agonist, and exenatide for publications up to 22 May 2015. Supporting data were obtained from additional searches for albiglutide, dulaglutide, liraglutide and lixisenatide as well as from the bibliographies of key articles.Findings:Short-acting GLP-1R agonists produce greater reductions in postprandial glucose levels by slowing gastric emptying, whereas long-acting GLP-1R agonists produce greater reductions in fasting blood glucose by stimulating insulin secretion from the pancreas. These characteristics can be exploited to provide individualized treatment to patients. A large body of evidence supports the benefits of short- and long-acting exenatide as add-on therapy in patients with inadequate glycemic control despite maximum tolerated doses of metformin and/or sulfonylurea. Exenatide is generally well tolerated and no new safety concerns were identified during long-term follow-up of up to 5 years. A limitation of this review of short-and long-acting GLP-1 receptor agonists is that it focuses on exenatide rather than all the drugs in this class. However, the focus on a single molecule helps to avoid any confusion that may be introduced as a result of differences in molecular structure and size.Conclusions:Short-acting GLP-1R agonists including exenatide are well suited to patients with type 2 diabetes with exaggerated postprandial glucose excursions and for co-administration with basal insulin therapy. Long-acting GLP-1R agonists including once weekly exenatide offer greater convenience and are well suited to patients who require specific control of fasting hyperglycemia.

Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation

Double Layer Spherical Nanoparticles with Hyaluronic Acid Coating to Enhance Oral Delivery of Exenatide in T2DM Rats.

Preparation, Characterization, and Pharmacodynamics of Exenatide-Loaded Poly(DL-lactic-co-glycolic Acid) Microspheres

Acylation of Exenatide by Glycolic Acid and its Anti-Diabetic Activities in db/db Mice

Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes

Exenatide-loaded PLGA Microspheres with Improved Glycemic Control: in Vitro Bioactivity and in Vivo Pharmacokinetic Profiles after Subcutaneous Administration to SD Rats.

Oral Delivery of Exenatide Via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate.

Exenatide Loaded PLGA Microspheres for Long-Acting Antidiabetic Therapy: Preparation, Characterization, Pharmacokinetics and Pharmacodynamics

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity

Exenatide-loaded Glucose-Responsive Microspheres for Intelligent Diabetic Therapy

In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.

A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.

Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.

Novel Lipid Side Chain Modified Exenatide Analogs Emerged Prolonged Glucoregulatory Activity and Potential Body Weight Management Properties.

Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.

Injectable sustained‐release poly(lactic‐co‐glycolic acid) (PLGA) microspheres of exenatide prepared by supercritical fluid extraction of emulsion process based on a design of experiment approach

Comparative Studies on Exenatide-Loaded Poly (D,l-Lactic-co-glycolic Acid) Microparticles Prepared by a Novel Ultra-Fine Particle Processing System and Spray Drying

The Value of Short- and Long-Acting Glucagon-Like Peptide-1 Agonists in the Management of Type 2 Diabetes Mellitus: Experience with Exenatide

Development and Validation of A Reverse-Phase High Performance Liquid Chromatography Method for Determination of Exenatide in Poly(Lactic-Co-Glycolic Acid) Microspheres

Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy